McKesson Corp. (MCK) News
Filter MCK News Items
MCK News Results
|Loading, please wait...|
MCK News Highlights
- For MCK, its 30 day story count is now at 110.
- Over the past 25 days, the trend for MCK's stories per day has been choppy and unclear. It has oscillated between 1 and 41.
- The most mentioned tickers in articles about MCK are DRUG, NXGN and PAY.
Latest MCK News From Around the Web
Below are the latest news stories about Mckesson Corp that investors may wish to consider to help them evaluate MCK as an investment opportunity.
Shares of Johnson & Johnson, AmerisourceBergen, McKesson, and Cardinal Health jumped Friday morning.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.
Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.
CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas, February 25, 2022--AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that each company has independently determined that there is sufficient participation by states and litigating political subdivisions to proceed with a comprehensive agreement to settle the vast majority of the opioid lawsuits filed by state and local governmental entities.
Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.
Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.
Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.
The following segment was excerpted from this fund letter. McKesson Corp (MCK) Shares of McKesson tacked on another 23% during the second half. Even after gaining 44% for the full year, the stock still trades at a 50% discount to the market. Like our Dollar Tree investment, investor sentiment around...